Form 8-K · Current Report · Filed 2024-10-31
Halozyme Reports Strong Q3 2024 Results and Raises Full-Year Guidance
Halozyme Therapeutics, Inc. reported a 34% increase in total revenue to $290 million and a 67% increase in net income to $137 million for the third quarter of 2024. The company raised its full-year 2024 guidance for total revenue, adjusted EBITDA, and non-GAAP diluted EPS. Royalty revenue increased by 36% to $155 million, driven by the growth in DARZALEX SC and Phesgo. Halozyme also announced several significant collaborations and regulatory approvals for its ENHANZE drug delivery technology.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-24-000049
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$50.59
Next session
+13.0%
Since filing
+117.9%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Exhibits (1)
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.